Pharmaron Beijing
Pharmaron Beijing Co., Ltd., commonly referred to as Pharmaron, is a leading contract research organisation (CRO) headquartered in Beijing, China. Established in 2004, the company has rapidly expanded its operational footprint across major regions, including North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Pharmaron offers a comprehensive suite of services, including drug discovery, development, and manufacturing, with a focus on small molecules and biologics. Its unique integration of advanced technologies and scientific expertise enables clients to accelerate their drug development processes. Notably, Pharmaron has achieved significant milestones, such as successful collaborations with global pharmaceutical companies, solidifying its reputation for excellence in the industry. With a commitment to innovation and quality, Pharmaron continues to enhance its market position as a trusted partner in the life sciences arena.
DitchCarbon Score
How does Pharmaron Beijing's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaron Beijing's score of 50 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmaron Beijing's reported carbon emissions
In 2023, Pharmaron Beijing reported total greenhouse gas emissions of approximately 395,142,930 kg CO2e, with emissions distributed across various scopes: 34,755,680 kg CO2e (Scope 1), 216,740,300 kg CO2e (Scope 2), and 395,142,930 kg CO2e (Scope 3). The combined Scope 1 and 2 emissions totalled about 251,495,980 kg CO2e. Pharmaron has set ambitious climate commitments, aiming for near-zero emissions in both Scope 1 and Scope 2 by 2025. Additionally, the company has pledged to achieve a 54.6% reduction in absolute Scope 1 and 2 emissions by 2033, using 2023 as the base year. Long-term goals include a 90% reduction in absolute Scope 1 and 2 emissions by 2050, with a 97% reduction in Scope 3 emissions per million CNY value added. These targets align with the Science Based Targets initiative (SBTi) and reflect Pharmaron's commitment to reaching net-zero greenhouse gas emissions across its value chain by 2050. The company is actively working towards these goals, demonstrating a strong commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 48,007,050 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 267,941,280 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmaron Beijing is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
